{"id":"isis-gcgrrx","_chembl":{"chemblId":"CHEMBL499450","moleculeType":"Small molecule","molecularWeight":"7343.20"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Glucagon receptor (GCGR)","explanation":"The drug works by binding to GCGR mRNA, leading to its degradation and reduced expression of the glucagon receptor. By blocking glucagon signaling, it aims to decrease hepatic glucose output and improve glycemic control in patients with metabolic disorders.","oneSentence":"ISIS-GCGRRx is an antisense oligonucleotide that inhibits glucagon receptor expression to reduce hepatic glucose production."},"_scrapedAt":"2026-03-28T01:56:45.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123306,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"semaglutide","brand":"Ozempic","company":"Novo Nordisk","rationale":"GLP-1 receptor agonist for type 2 diabetes with glucose-lowering effects"},{"name":"tirzepatide","brand":"Mounjaro","company":"Eli Lilly","rationale":"Dual GIP/GLP-1 receptor agonist for type 2 diabetes management"},{"name":"metformin","brand":"Glucophage","company":null,"rationale":"First-line oral agent that reduces hepatic glucose production"}],"description":"ISIS-GCGRRx is an investigational antisense oligonucleotide developed by Ionis Pharmaceuticals targeting the glucagon receptor (GCGR). The drug is being evaluated in Phase 2 clinical trials for potential treatment of metabolic disorders, particularly type 2 diabetes, by reducing glucagon signaling.","indications":{"approved":[{"status":"investigational","condition":"Type 2 diabetes mellitus","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT02583919","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":79},{"nctId":"NCT02824003","phase":"PHASE2","title":"Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2016-04","conditions":"Type 2 Diabetes","enrollment":15},{"nctId":"NCT01885260","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ISIS 449884"],"phase":"phase_2","status":"active","brandName":"ISIS-GCGRRx","genericName":"ISIS-GCGRRx","companyName":"Ionis Pharmaceuticals, Inc.","companyId":"ionis-pharmaceuticals-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}